STO · ATT.ST
Attendo AB (publ)
SEK 117.20+SEK 0.40 (+0.34%)
Attendo AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 9.98% below the high.
Loading market information…
STO · PLUN.ST · SEK
Stock price, earnings
Quote as of Oct 31, 2025, 11:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
ProstaLund AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 98.2% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow ProstaLund AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ProstaLund AB (publ) specializes in the creation and distribution of urological medical devices, primarily targeting patients with benign prostatic hyperplasia (BPH) in Sweden and across global markets. Their product offerings include CoreTherm, a thermal treatment method for BPH, and Gepan instill, designed for addressing chronic bladder inflammation. These solutions are utilized in hospitals and various clinical settings. Established in 1991, the company is based in Lund, Sweden, and operates as a subsidiary of Farstorps Gard Forvaltnings AB.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:01 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Feb 16, 2024 |
| -SEK 0.04+96.17% vs estimate |
| SEK 6.44M+6.3% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 117.20+SEK 0.40 (+0.34%)
Attendo AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 9.98% below the high.
SEK 183.70+SEK 0.40 (+0.22%)
Ambea AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 3.21% below the high.
SEK 70.90+SEK 0.30 (+0.42%)
Humana AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 8.87% below the high.
SEK 3.32+SEK 0.12 (+3.75%)
Senzime AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 46.79% below the high.
SEK 0.18+SEK 0.00 (+2.0%)
Acarix AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 46.65% below the high.
SEK 12.50-SEK 0.15 (-1.19%)
SciBase Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 76.85% below the high.
SEK 0.06-SEK 0.00 (-0.51%)
Episurf Medical AB’s quoted price sits in the lower half of its reported 52-week range, 79.66% below the high.
$0.00$0.00 (0.0%)
IMAC Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.76% below the high.
